DoseMeRx addresses one of the most dangerous intersections in clinical medicine: dosing drugs with narrow therapeutic windows in patients with variable or impaired renal function. The platform uses Bayesian pharmacokinetic modeling to calculate individualized doses based on patient-specific parameters — weight, renal function, drug levels, and population pharmacokinetic models — rather than relying on standard dosing tables that don't account for individual variation.
The clinical case for precision dosing is strongest in nephrology, where fluctuating GFR directly affects drug clearance. Vancomycin dosing is the canonical example: the 2020 ASHP/IDSA vancomycin guidelines explicitly recommend Bayesian software for AUC-guided dosing, replacing trough-only monitoring. DoseMeRx is the most widely adopted platform for implementing this recommendation, with peer-reviewed evidence demonstrating improved target attainment and reduced nephrotoxicity compared to traditional dosing methods.
Beyond vancomycin, DoseMeRx supports dosing for aminoglycosides (gentamicin, tobramycin, amikacin), anticoagulants (warfarin), immunosuppressants (tacrolimus, cyclosporine, mycophenolate), antiepileptics (phenytoin, valproate), and other narrow therapeutic index drugs that are particularly hazardous in renal impairment. The platform integrates with major EHR systems and is deployed in over 300 hospitals globally.
This review evaluates DoseMeRx exclusively for its nephrology applications, where renal dose adjustment and pharmacokinetic optimization are central to patient safety. As a specialized precision dosing platform rather than a general clinical decision support tool, it was not included in our overall CDS rankings. Within nephrology, DoseMeRx is a well-established option for individualized drug dosing in patients with renal impairment.